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SUMMARY: Hypertension is one of the most important risk factors associated with the development of cardio-
vascular diseases. Numerous studies have revealed that a diet enriched in olive oil can have a beneficial effect on 
blood pressure. This systematic review includes the effects of olive oil on blood pressure in individuals without 
previous cardiovascular events. Liquid oil shows a decrease in blood pressure, while capsules have not produced 
any effect. Diastolic blood pressure decreased after the consumption of olive oil, -0.73 mm Hg, 95% CI (-1.07, 
-0.40); p < 0.001, I2 = 86.9%, with high heterogeneity among the included studies. This reduction was mainly 
due to extra virgin olive oil (EVOO) from 10 ml to 50 ml/day: -1.44 mm Hg, 95% CI (-1.89, -1.00); p < 0.001. 
Regarding systolic blood pressure the observed decrease is not statistically significant. Further studies on the 
consumption of EVOO are needed to confirm these results.
KEYWORDS: Diastolic Pressure; Hypertension; Olive oil; Randomized Controlled Trial; Systematic review; Systolic pressure
RESUMEN: Efectos del aceite de oliva en la presión arterial: revisión sistemática y metaanálisis. La hipertensión 
es uno de los factores de riesgo más importantes asociados con al desarrollo de enfermedades cardiovasculares. 
Numerosos estudios han revelado que una dieta enriquecida en aceite de oliva puede producir un efecto bene-
ficioso sobre la tensión arterial. En esta revisión sistemática se recogen los efectos del aceite de oliva sobre la 
tensión arterial en individuos sin eventos cardiovasculares previos. Es el aceite líquido el que ha mostrado los 
beneficios, mientras que las cápsulas no han producido ningún efecto. La tensión arterial diastólica disminuyó 
después del consumo de aceite de oliva, -0.73 mm Hg, IC 95% (-1.07, -0.40); p < 0.001, I2 = 86.9%, con elevada 
heterogeneidad entre los estudios incluidos. Esta reducción se debió principalmente al aceite de oliva virgen 
extra (AOVE) de 10 ml a 50 ml / día: -1.44 mm Hg, IC 95% (-1.89, -1.00); p < 0.001. En lo que se refiere a la ten-
sión arterial sistólica el descenso producido no ha sido estadísticamente significativo. Se necesitan más estudios 
sobre el consumo de AOVE para confirmar estos resultados.
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sistólica; Revisión sistemática
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1. INTRODUCTION
Hypertension is one of the most important risk 
factors associated with the development of cardio-
vascular disease. The threshold for the diagnosis of 
hypertension is a systolic blood pressure (SBP) of at 
least 140 mm Hg, a diastolic blood pressure (DBP) 
of at least 90 mm Hg, or both (Poulter et al., 2015). 
Hypertension increases the risk of stroke, coro-
nary heart disease, sudden death, heart failure and 
peripheral arterial disease (Mancia et al., 2013). A 
change in lifestyle can be an effective intervention to 
control blood pressure. The preventive measures to 
adopt are restriction of salt in the diet, moderation 
in alcohol consumption, abundant fruit consump-
tion, control of weight, regular physical activity, and 
smoking cessation (Dickinson et al., 2006). 
Several epidemiological studies have analyzed the 
relationship between monounsaturated fatty acid 
(MUFA) consumption, such as olive oil, and hyper-
tension (Alonso et al., 2006). In 2005, the OmniHeart 
study compared three diets: one rich in carbohydrates, 
another rich in vegetable proteins, and the third with 
MUFA. The diets rich in vegetable proteins and 
MUFA compared with the carbohydrate diet reduced 
blood pressure and improved the lipid profile (Appel 
et al., 2005). The International Study of Macro/
Micronutrients and Blood Pressure (INTERMAP) is 
a multicenter cross-sectional study of 4680 men and 
women in which linear regression analyses showed a 
significant inverse relationship between total MUFA 
intake and DBP. A Spanish study showed that the 
consumption of vegetable oleic acid, with a daily 
intake of 13 g/day, was associated with a decrease in 
SBP (-0.70 mmHg) and DBP (-0.57mm Hg) (Miura 
et al., 2013). In the PREDIMED (Prevención con 
Dieta Mediterránea) clinical trial both SBP and DBP 
decreased 2.3 and 1.2 mm Hg, respectively, after one 
year of follow-up (Doménech et al., 2014). 
The consumption of olive oil is very common in 
Mediterranean countries. It is associated with the 
Mediterranean diet and it is not clear whether the 
effects of olive oil are due to the oil itself  or to the 
whole diet pattern. The objective of this study is to 
assess whether the consumption of olive oil reduces 
blood pressure in adults without previous cardio-
vascular events.
2. METHODS
2.1. Design
We carried out a systematic review and meta-
analysis following the recommendations established 
by the PRISMA statement (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyzes) 
(Moher et al., 2009). A systematic review protocol 
was developed, not registered a priori, and not mod-
ified after the beginning of the review process. 
2.2. Eligibility criteria
We used the following inclusion criteria: a) partici-
pants: adult population with at least 18 years of age 
without previous cardiovascular events; b) interven-
tion: diet enriched with olive oil for at least 12 weeks 
vs. diet enriched with other fat; c) outcome measures: 
SBP or DBP; d) design of included studies: random-
ized controlled trials (RCTs). We have included both 
healthy individuals with cardiovascular risk factors or 
with other non-cardiovascular pathology.
2.3. Exclusion criteria
We exclude studies in which the intervention was 
carried out in cardiovascular patients because they 
experience a profound change in their lifestyle, includ-
ing diet, not comparable with healthy subjects or with 
other types of diseases. Animal studies were discarded.
2.4. Research methods
The following electronic databases were searched 
from their inception through April 10, 2018: 
PubMed, Embase, Cochrane plus, Web of Science, 
Ovid, Scopus, VHL, TDR. The language of publi-
cation was not restricted.
The search strategy was carried out through the 
combination of keywords related to olive oil intake 
(olive oil), and the different expected results: hyper-
tension (arterial pressure, hypertension, blood pres-
sure, DBP, SBP), and the design of adequate studies 
for inclusion (randomized controlled trial, system-
atic review, meta-analysis). Reference lists of identi-
fied original articles were searched manually. Table 1 
shows the search strategy for the databases.
TABLE 1. Search strategy
PubMed, Web of Science, Embase, Ovid, Biblioteca Cochrane 
plus, Scopus, VHL, TDR
1. olive oil
2. Arterial Pressure
3. Hypertension
4. Blood Pressure
5. Diastolic Pressure
6. Systolic Pressure
7. 2# OR 3# OR 4# OR 5# OR 6#
8. 1# AND 7#
9. 8# AND (Randomized Controlled Trial OR systematic 
review OR Meta-Analysis)
10. 9# AND humans
VHL
1. olive oil
2. hypertension
3. Humans
4. 1# AND 2# AND 3#
Effects of olive oil on blood pressure: A systematic review and meta-analysis • 3
Grasas Aceites 69 (4), October–December 2018, e272. ISSN-L: 0017–3495 https://doi.org/10.3989/gya.0105181
2.5.  Risk of bias in individual studies
We used the Cochrane risk of bias tool to assess 
risk of bias within the following domains: selection 
bias, performance bias, detection bias, attrition bias, 
reporting bias, and other bias (Higgins and Green, 
2011). Table 2 shows the studies after the validity 
analysis.
2.6.  Data extraction and management
Two researchers made the selection of articles 
independently. Discrepancies were discussed with 
a third review author until consensus was reached. 
The following data were extracted from each study: 
authors, year of publication, country of implemen-
tation, duration, amount of olive oil intake in the 
experimental group and fat in the control one, char-
acteristics and number of participants in each inter-
vention applied, SBP and DBP (Table 2).
2.7. Data synthesis
The outcome parameter was the change in 
blood pressure regarding baseline values; the 
mean standard error of  the change was computed. 
Mean differences (MDs) were pooled using a 
fixed effects model. Heterogeneity between stud-
ies results was tested using the Q test. The propor-
tion of  heterogeneity was quantified with the I2 
parameter. I2 > 50 % was considered to represent 
considerable heterogeneity. Metarregression was 
performed to explore the causes of  heterogeneity. 
We applied Egger’s method to determine the pos-
sible existence of  publication bias. All data were 
analyzed using Stata 14 SE program (College 
Station, TX, USA).
3. RESULTS
3.1. Literature research
The search identified 872 studies, 687 of which 
were identified in different databases: 119 in PubMed, 
23 in Embase, 32 in the Cochrane Plus Library, 167 
in the Web of Science, 35 in Ovid, 232 in Scopus, 
and 79 in VHL; while 185 were located through the 
grey literature of TDR and hand searched for refer-
ences. After the exclusion of duplicates, 691 studies 
were evaluated. 27 studies were reviewed in full text, 
and 15 studies were finally included. The reasons for 
exclusion are detailed in Figure 1.
3.2. Characteristics of studies included in systematic 
review
Fifteen studies were included in the systematic 
review and meta-analysis (Kristensen et al., 2016, 
Rozati et al., 2015, Lee et al., 2015, Venturini et al., 
2015, Ceriello et al., 2014, Toledo et al., 2013, Singhal 
et al., 2013, Tapsell et al., 2013, Konstantinidou 
et  al., 2010, Taylor et al., 2006, Rasmussen et al., 
2006, Olsen et al., 2000, Ferrara et al., 2000, Prisco 
et al., 1998, Bonnema et al., 1995). Table 2 shows 
a summary of the information extracted from the 
included studies. The designs used by the studies 
were: double blind parallel RCTs (Kristensen et al., 
2016, Lee et al., 2015, Singhal et al., 2013, Taylor 
et al., 2006, Olsen et al., 2000, Prisco et al., 1998, 
Bonnema et al., 1995), double-blind,  random-
ized crossover study (Ferrara et al., 2000), and non-
blinded RCTs (Rozati et al., 2015, Venturini et al., 
2015, Ceriello et al., 2014, Toledo et al., 2013, Tapsell 
et al., 2013, Konstantinidou et al., 2010, Rasmussen 
et al., 2006). The follow-up ranged from 12 weeks 
to 4 years. The countries in which the studies were 
developed were Spain (Ceriello et al., 2014, Toledo 
et al., 2013, Konstantinidou et al., 2010), Denmark 
(Kristensen et al. 2016, Bonnema et al.,1995), Italy 
(Ferrara et al., 2000, Prisco et al., 1998), United 
Kingdom (Singhal et al., 2013, Taylor et al., 2006), 
South Korea (Lee et al., 2015), USA (Rozati et al., 
2015), Brazil (Venturini et al., 2015), Australia 
(Tapsell et al., 2013), and two multinational stud-
ies: Denmark, United Kingdom, Sweden, Italy, 
Netherlands, Belgium, Russia and Norway (Olsen 
et al., 2000); and Finland, Denmark, Italy, Australia 
and Sweden (Rasmussen et al., 2006). 
The fifteen studies included 6651 participants: 
3358 had ingested olive oil and 3293 were fed the 
control diet. Four studies had more than two arms; in 
these studies the following branches were discarded 
for the present review: in the PREDIMED study the 
branch with Mediterranean diet plus nuts (Toledo 
et al., 2013), refined olive oil (Konstantinidou et al., 
2010), hypocaloric diet plus fish (Tapsell et  al., 
2013), and pregnant women with fewer weeks of 
administration (Olsen et al., 2000). Venturini et al., 
(2015)  gives their outcomes as mean and inter-
quartile range and they could not be included in 
meta-analysis. Men and women were pooled in the 
analyses.
The participants were adults without cardio-
vascular events. Some participants had cardiovas-
cular risk factors such as overweight or obesity 
(Rozati et al., 2015, Tapsell et al., 2013, Taylor 
et  al., 2006), diabetes mellitus (Ceriello et al., 
2014), incipient or established diabetic nephrop-
athy (Lee et al., 2015, Bonnema et al., 1995) 
or more than three cardiovascular risk factors 
(Toledo et al., 2013), hypertension (Ferrara et al., 
2000, Prisco et al., 1998), metabolic syndrome 
(Venturini et al., 2015) and psoriatic arthritis 
(Kristensen et al., 2016). Three studies were per-
formed in healthy adults (Singhal et al., 2013, 
Konstantinidou et al., 2010, Rasmussen et al., 
2006). Olsen et al., (2000) recruited twin pregnan-
cies and pregnancy induced hypertension. 
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3.3. Types of interventions
The olive oil was administered in capsules of 1-6 g/
day (Kristensen et al., 2016, Lee et al., 2015, Singhal 
et al., 2013, Tapsell et al., 2013, Taylor et al., 2006, 
Rasmussen et al., 2006, Olsen et al., 2000, Prisco 
et al., 1998, Bonnema et al., 1995), and in liquid form 
as extra virgin olive oil (EVOO) from 10 ml to 50 ml/
day (Rozati et al., 2015, Venturini et al., 2015, Ceriello 
et al., 2014, Toledo et al., 2013, Ferrara et al., 2000, 
Konstantinidou et al., 2010), in the context of different 
types of diets, such as the American diet (Rozati et al., 
2015), or the Mediterranean diet (Konstantinidou 
et  al., 2010, Toledo et al., 2013, Prisco et al., 1998). 
The studies that supplemented liquid oil provided it 
as EVOO, while the studies with capsule supplement 
provided it with olive oil.
The control groups took both capsules, liquid 
oil, habitual diet and low-fat diet. The controls 
took capsules with different fatty acids: microalgae 
and palmitic acid (Singhal et al., 2013), conjugated 
linoleic acid (Taylor et al., 2006), docosahexae-
noic acid (DHA) and eicosapentaenoic acid (EPA) 
(Kristensen et al., 2016, Lee et al., 2015, Tapsell 
et  al., 2013, Bonnema et al., 1995, Rasmussen et 
al., 2006, Olsen et al., 2000, Prisco et al., 1998). 
In liquid form the next fats were administered to 
the control groups: corn oil, soybean oil and but-
ter (Rozati et al., 2015), and sunflower oil (Ferrara 
et al., 2000). Finally, in four studies, no supple-
ment was provided to the control groups: habitual 
diet (Venturini et al., 2015, Konstantinidou et al., 
2010), and low fat diet (Ceriello et al., 2014, Toledo 
et al., 2013). 
The diet administered was adequate to the energy 
requirements, except in Tapsell et al., (2013) who 
administered a hypocaloric diet with 1750 (SD 417) 
kcal and 1600 (SD 355) kcal in the olive oil and 
control groups, respectively. Physical activity was 
not restricted in the included studies; they were 
requested to maintain their regular routine of physi-
cal activity. Tapsell et al., (2013), recommended 
walking for 30-minutes three days a week, with simi-
lar results among groups.
3.4. Outcome measures
Fourteen studies assessed DBP and SBP, and 
one study only DBP (Olsen et al., 2000). No adverse 
events were mentioned: only nine participants in 
the n-3 polyunsaturated fatty acid (PUFA) supple-
mented group and six participants in the olive oil 
group reported mild gastrointestinal adverse effects 
in Kristensen et al., (2016).
FigurE 1. Flow chart of study procedure. Randomized controlled studies of at least three months duration, not developed in 
animals, or in individuals with previous cardiovascular events have been included. Other interventions have been excluded, such as 
the administration of other non-ingested supplements or the intake of two oils together at the same time.
No of records identified
through database searching N = 687 
No of additional records
identified through other sources N = 185
No of records after duplicates removed
N = 181
N = 691 No of records screened
No of full-text articles assesed for
eligiblity N = 27
No of studies included in qualitative and quantitative synthesis N = 15
Excluded N = 12:
 - another study N = 1
 - other interventions N = 3
 - results of the same study N = 7
 - other participants N = 1
No of records excluded N = 664
 - other studies N = 334
 - other interventions N = 142
 - other outcomes N = 66
 - other length of follow-up N = 14
 - other participants N = 14
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3.5. Risk of bias in individual studies
 We used the Cochrane risk of bias tool (Higgins 
and Green, 2011) to assess all studies for their risk 
of bias within the following domains: selection bias, 
performance bias, detection bias, attrition bias, 
reporting bias, and other bias. Figure 2 provides an 
overview of the risk of bias assessment. Two studies 
had high risk for selective reporting bias (Venturini 
et al., 2015, Olsen et al., 2000) and one study was 
classified as high risk for attrition bias (Tapsell 
et al., 2013). An intention-to-treat analysis was per-
formed. The included studies were considered as 
having low risk for bias.
3.6. Results of the meta-analysis
Olive oil did not decrease SBP more than other 
fat, MDs = -0.11, CI 95 % (-0.68, 0.46), I2 = 85.1%; p 
heterogeneity < 0.001. The studies dispensed liquid 
olive oil or capsules. To identify the effect of the two 
kinds of supplementation meta-analysis was strati-
fied by this variable (capsules and oil) (Figure 3): no 
significant effect was observed either for capsules or 
liquid on SBP. 
Olive oil showed a significant decrease in DBP 
with a fixed effects model of -0.73 mm Hg, 95% CI 
(-1.07, -0.40); p < 0.001; I2 = 84.5%; p heterogene-
ity < 0.001. This effect was mainly due to liquid 
FigurE 2. Risk of bias. For each study, each domain of bias is indicated as: low risk of bias in green, unclear risk of bias in yellow, 
and high risk of bias, in red.
Venturini
Toledo
Taylor
Tapsell
Singhal
R
ozati
R
asm
ussen
Prisco
O
lsen
Lee
Kristensen
Konstantinidou
Ferrara
Ceriello
Bonnem
a
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
FigurE 3. Meta-analysis of the effect of olive oil on systolic blood pressure, stratified by type of supplementation. The mean 
standard error of the change was computed. For each study, the shaded square represents the point estimate of the intervention 
effect. The individuals who have taken olive oil are located to the left of the forest plot.
Studies
Capsules
I-V Subtotal (I-squared = 87.5%, p = 0.000)
I-V Subtotal (I-squared = 83.2%, p = 0.000)
I-V Overall (I-squared = 85.1%, p = 0.000)
Heterogeneity between groups: p = 0.419
D+L Subtotal
D+L Subtotal
D+L Overall
-14.2 0 14.2
-0.55 (-2.34, 1.23)
-2.60 (-5.26, 0.06)
0.90 (-2.03, 3.83)
2.44 (0.22, 4.66) 6.68
-4.60 (-11.77, 2.57) 0.64
-2.00 (-3.31, -0.69) 19.24
-2.00 (-6.86, 2.86) 1.39
0.60 (-1.96, 3.16) 5.02
-2.50 (-5.59, 0.59) 3.45
8.00 (5.30, 10.70) 4.52
7.00 (-0.21, 14.21) 0.63
0.17 (-0.72, 1.06) 41.57
-6.00 (-9.62, -2.38) 2.50
-0.30 (-2.26, 1.66) 8.55
0.39 (-0.48, 1.26) 43.44
-2.00 (-5.75, 1.75) 2.34
-8.00 (-12.54, -3.46) 1.60
-0.31 (-1.06, 0.44) 58.43
-0.11 (-0.68, 0.46) 100.00
Liquid
Year
Kristensen 2016
Lee 2015
Singhal 2013
Tapsell 2013
Taylor 2006
Rasmussen 2006
Prisco 1998
Bonnema 1995
Rozati 2015
Toledo 2013
Ceriello 2014
Konstantinidou 2010
Ferrara 2000
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%
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(I-V)
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oil EVOO: a reduction of -1.44 mm Hg, 95% CI 
(-1.89, -1.00); p < 0.001; with a high heterogeneity, 
I2 = 86.9%; p heterogeneity < 0.001. The olive oil 
in capsules had no significant influence on DBP, 
0.14 mm Hg, 95% CI (-0.35, 0.64), I2 = 76.2%, p = 
0.5 (Figure  4). A meta-regression was performed 
to inquire the causes of heterogeneity. Neither the 
quantity of grams of olive oil on SBP (p = 0.35) or 
DBP (p = 0.51), nor the year of publication (p = 0.27 
and p = 0.70, respectively), seem to be the cause of 
the heterogeneity found among the studies selected 
for the meta-analysis. Among the causes of hetero-
geneity are the different diets, and the characteristics 
of the patients for whom the studies were developed.
3.7. Risk of bias across studies (publication bias)
Egger’s method showed p values of 0.67 and 0.23 
for SBP and DBP, respectively. 
4. DISCUSSION 
In this systematic review of 6651 participants 
without previous cardiovascular events in 15 RCTs, 
comparing a diet enriched with olive oil versus a diet 
enriched with other fats, a significant reduction in 
DBP was observed, with high heterogeneity. This 
heterogeneity may be due to differences in the diets 
of control groups, characteristics of the populations 
(very different countries, with different risk factors, 
etc.), and the type of supplementation of olive oil. 
The EVOO seems to be the main factor responsi-
ble for the decrease in DBP. The PREDIMED trial 
(Toledo et al., 2013) is the more influential study 
in the pooled results with a weight of 43.44% and 
46.57% for SBP and DBP, respectively, and with 
more of the 70% of all subjects. The use of a ran-
dom effects model implies giving a higher weight for 
much smaller studies, and more prone to bias than 
the PREDIMED. That is the reason we relied on the 
fixed effects model. 
Considering the individual studies, a higher 
decrease in SBP was obtained with liquid EVOO, 
about 40 g in men and 30 g in women, compared 
to sunflower oil (Ferrara et al., 2000): -8 mm Hg in 
SBP, CI 95% (-12.5, -3.46), and -6 mm Hg in DBP, 
CI 95% (-8.22, -3.78). In another study (Rozati 
et al., 2015), EVOO (39 ± 7 g/day) significantly 
reduced SBP in -6 mm Hg, 95% CI (-9.62,-2.38), 
when compared with corn oil, soybean oil and but-
ter together in an American diet. A lower reduction 
was observed with olive oil capsules (4 g) versus 
capsules of microalgae and palmitic acid: -2 mm Hg 
in SBP, 95% CI (-3.31, -0.69) (Singhal et al., 2013). 
In the PREDIMED trial after 3.8 years of follow-
up (Toledo et al., 2013), liquid EVOO decreased 
DBP by -1.53 mm Hg, 95% CI (-2.01, -1.04). This 
reduction is similar to that found with olive oil 
capsules, compared to capsules containing fish oil 
(Rasmussen et al., 2006), -2.5 mm Hg in DBP, 95% 
CI (-4.86, -0.14), and lower than reported in obese 
subjects (Tapsell et al., 2013): -4 mm Hg in DBP, 
95% CI (-6.97, -1.03).
The study by Venturini et al., (2015), which could 
not be pooled as a mean difference could not be 
obtained, observed interesting results comparing 
FigurE 4. Meta-analysis of olive oil on diastolic blood pressure, stratified by type of supplementation. The mean standard error of 
the change was computed. For each study, the shaded square represents the point estimate of the intervention effect. The individuals 
who have taken olive oil are located to the left of the forest plot.
Studies
Capsules
I-V Subtotal (I-squared = 76.2%, p = 0.000)
I-V Subtotal (I-squared = 86.9%, p = 0.000)
I-V Overall (I-squared = 84.5%, p = 0.000)
Heterogeneity between groups: p = 0.000
D+L Subtotal
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D+L Overall
-9.7 0 9.7
-0.21 (-1.24, 0.82)
3.00 (0.00, 6.00)
-0.65 (-1.85, 0.55) 7.60
4.60 (-0.50, 9.70) 0.42
0.00 (-0.92, 0.92) 12.81
-4.00 (-6.97, -1.03) 1.24
-0.90 (-3.00, 1.20) 2.48
-2.50 (-4.86, -0.14) 1.97
1.30 (-0.13, 2.73) 5.38
0.40 (-0.63, 1.43) 10.33
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0.14 (-0.35, 0.64) 44.59
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1.90 (0.08, 3.72) 3.32
-1.53 (-2.01, -1.04) 46.57
-6.00 (-8.22, -3. 78) 2.22
-1.00 (-3.57, 1.57) 1.65
-1.44 (-1.89, -1.00) 55.41
1.22
-0.73 (-1.07, -0.40) 100.00
-1.31 (-3.43, 0.81)
Liquid
Year
Kristensen 2016
Lee 2015
Singhal 2013
Tapsell 2013
Taylor 2006
Rasmussen 2006
Olsen PIH 2000
Olsen Twins 2000
Prisco 1998
Bonnema 1995
Rozati 2015
Toledo 2013
Ceriello 2014
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EVOO with a regular diet in participants with meta-
bolic syndrome. They reported a decrease in the 
mean SBP of -5 mm Hg and -14 mm Hg in DBP.
Other studies with interventions of shorter dura-
tion than 12 weeks, not included in this review, 
showed significant reductions in blood pressure. 
In a double-blind crossover trial of 24 women, 
Moreno Luna et al., (2012) examined the influence 
of oil with high content in polyphenols on blood 
pressure: EVOO reduced SBP by -7.91 ± 9.51 mm 
Hg and DBP -6.65 ± 6.63 mm Hg. These effects are 
similar to those observed in a systematic review on 
the effect of first-line antihypertensive drugs choice 
(Wright and Musini, 2009). The effect of poly-
phenols has also been evaluated in a group of 160 
healthy men from the North, Center and South of 
Europe (Bondia-Pons et al., 2007) in a randomized 
cross-over trial with three intervention periods: 25 
ml/day of olive oil were administered with different 
concentrations of polyphenols. Both SBP and DBP 
decreased after consuming olive oil for nine weeks. 
In addition, the properties of virgin olive oil were 
evaluated in the SOLOS study in 40 men with stable 
coronary disease (Fitó et al., 2005): SBP decreased 
after the intake of EVOO (p < 0.001), with no 
change in DBP. A systematic review on the effects 
of virgin olive oil polyphenols found significant dif-
ferences in SBP and no effect on DBP (Hohmann 
et  al., 2015), although the number of pooled sub-
jects is small, 69. 
Olive oil seems to inhibit the activity of angioten-
sin-converting enzymes, and blocks the binding to 
angiotensin II receptor, and this hypotensive activity 
was demonstrated in studies on animals or humans 
(Patten et al., 2016).
Among the strengths of this study is the exhaus-
tive search developed without language restriction, 
the number of studies reviewed, and the quality of 
the included studies. The results could be extended 
to healthy subjects, with cardiovascular risk factors, 
type 2 diabetes, hypertension, overweight, obesity, 
and countries with distinct economic and social 
development. The main limitation of our system-
atic review is the heterogeneity among the studies. It 
could be justified because some studies have been car-
ried out in areas with regular consumption of olive 
oil and it is possible that the group control has also 
taken olive oil. In addition, some participants have 
taken antihypertensive treatment for their underly-
ing disease, thus decreasing the potential benefit of 
olive oil. Toledo et al., 2013, developed a study on 
individuals with different cardiovascular risk fac-
tors, including hypertension for which they need 
antihypertensive therapy, although the individuals 
were distributed into similar percentages between 
the intervention and control groups, 1666 (68%) 
patients in the extra virgin olive oil group and 1666 
(70.9%) in the control group. Likewise, in Ferrara 
et al., 2000, did a randomized crossover study in 
which there were basic conditions for all individu-
als. At the end of the follow-up, daily drug dosage 
was significantly reduced in the EVOO group, and 
34.7% needed no antihypertensive therapy, while all 
patients required treatment during the sunflower oil 
diet. Physical activity may also vary among different 
populations. 
Nevertheless, we consider that the number of 
studies on olive oil and blood pressure is still small. 
The intake of EVOO of between 10-50 ml per day 
can reduce diastolic blood pressure in healthy indi-
viduals or those with cardiovascular risk factors, 
even in hypertensive patients, and can be an impor-
tant therapeutic tool. Further studies on EVOO are 
needed to reduce heterogeneity and consolidate the 
results.
5. CONCLUSIONS
The present meta-analysis provides evidence for 
a beneficial effect of EVOO on blood pressure in 
participants without cardiovascular events. Healthy 
individuals or those with cardiovascular risk factors 
can benefit from a reduction in DBP if  they con-
sume olive oil for at least three months.
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